Does targeting VEGF improve the lives of patients with metastatic breast cancer? Since the E2100 trial, there has been uncertainty about the benefit and toxicities of anti-VEGF therapy. By evaluating the RIBBON-1 trial results, we ask is such therapy failing, and are we considering all variables when scrutinizing the data?
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Rational design of non-resistant targeted cancer therapies
Scientific Reports Open Access 24 April 2017
-
A streamlined search technology for identification of synergistic drug combinations
Scientific Reports Open Access 29 September 2015
-
Rapid optimization of drug combinations for the optimal angiostatic treatment of cancer
Angiogenesis Open Access 01 April 2015
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Robert, N. J. et al. RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2–negative, locally recurrent or metastatic breast cancer. J. Clin. Oncol. 29, 1252–1260 (2011).
Miller, K. et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N. Engl. J. Med. 357, 2666–2676 (2007).
Miles, D. W. et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J. Clin. Oncol. 28, 3239–3247 (2010).
Pazdur, R. Memorandum to the file BLA 125 085 Avastin (bevacizumab). FDA Center for Drug Evaluation and Research [online], (2010).
Gonzalez-Angulo, A. M. & Hortobagyi, G. N. Optimal schedule of paclitaxel: weekly is better. J. Clin. Oncol. 26, 1585–1587 (2008).
Burstein, H. J. Bevacizumab for advanced breast cancer: all tied up with a RIBBON? J. Clin. Oncol. 29, 1232–1235 (2011).
Miles, D. W. et al. Final overall survival results from the randomised, double-blind, placebo-controlled, phase III AVADO study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of locally recurrent or metastatic breast cancer [abstract 41]. Cancer Res. 69 (Suppl. 3), 495S (2009).
Colleoni, M. et al. Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1–98 study. J. Clin. Oncol. 29, 1117–1124 (2011).
Miles, D. et al. Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials. J. Clin. Oncol. 29, 83–88 (2011).
Ranpura, V., Hapani, S. & Wu, S. Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis. JAMA. 305, 487–494 (2011).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
G. N. Hortobagyi serves as a consultant for Genentech Roche. L. M. Ellis serves as an ad hoc consultant for Bristol-Myers Squibb, Genentech Roche and Genomic Health. A. M. Gonzalez-Angulo declares no competing interests.
Rights and permissions
About this article
Cite this article
Gonzalez-Angulo, A., Hortobagyi, G. & Ellis, L. Peaking beneath the surface of recent bevacizumab trials. Nat Rev Clin Oncol 8, 319–320 (2011). https://doi.org/10.1038/nrclinonc.2011.66
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2011.66
This article is cited by
-
Rational design of non-resistant targeted cancer therapies
Scientific Reports (2017)
-
A streamlined search technology for identification of synergistic drug combinations
Scientific Reports (2015)
-
Rapid optimization of drug combinations for the optimal angiostatic treatment of cancer
Angiogenesis (2015)
-
Pharmacodynamics of DT-IgG, a dual-targeting antibody against VEGF-EGFR, in tumor xenografted mice
Cancer Chemotherapy and Pharmacology (2012)
-
Unravelling the complexity of metastasis — molecular understanding and targeted therapies
Nature Reviews Cancer (2011)